CAS Number87848-99-5
SynonymsSemprex; (2E)-3-{6-[(1E)-1-(4-methylphenyl)-3-pyrrolidin-1-ylprop-1-en-1-yl]pyridin-2-yl}prop-2-enoic acid; (E)-6-[(E)-3-(1-Pyrrolidinyl)-1-p-tolylpropenyl]-2-pyridineacrylic Acid; Acrivastine; Acrivastinum; Acrivastina; (E)-3-[6-[(E)-1-(4-methylphenyl)-3-pyrrolidin-1-ylprop-1-enyl]pyridin-2-yl]prop-2-enoic acid; (2E)-3-{6-[(1E)-1-(4-Methylphenyl)-3-(1-pyrrolidinyl)-1-propen-1-yl]-2-pyridinyl}acrylic acid; (2E)-3-{6-[(1E)-1-(4-Methylphenyl)-3-(pyrrolidin-1-yl)prop-1-en-1-yl]pyridin-2-yl}acrylic acid; MFCD00869830; Acrivastin; Duact; (2E)-3-{6-[(1E)-1-(4-methylphenyl)-3-(pyrrolidin-1-yl)prop-1-en-1-yl]pyridin-2-yl}prop-2-enoic acid
Molecular FormulaC22H24N2O2
Molecular Weight348.44
Purity≥98 (HPLC)%
Density1.2±0.1 g/cm3
Boiling Point555.1±50.0 °C at 760 mmHg
Melting Point55.5-59.5 °C(lit.)
Appearancepowder
| Chemical & Physical Properties | |
|---|---|
| CAS Number | 87848-99-5 |
| Catalog No. | 2A-0202277 |
| Chinese Name | 阿伐斯汀 |
| Synonyms | Semprex; (2E)-3-{6-[(1E)-1-(4-methylphenyl)-3-pyrrolidin-1-ylprop-1-en-1-yl]pyridin-2-yl}prop-2-enoic acid; (E)-6-[(E)-3-(1-Pyrrolidinyl)-1-p-tolylpropenyl]-2-pyridineacrylic Acid; Acrivastine; Acrivastinum; Acrivastina; (E)-3-[6-[(E)-1-(4-methylphenyl)-3-pyrrolidin-1-ylprop-1-enyl]pyridin-2-yl]prop-2-enoic acid; (2E)-3-{6-[(1E)-1-(4-Methylphenyl)-3-(1-pyrrolidinyl)-1-propen-1-yl]-2-pyridinyl}acrylic acid; (2E)-3-{6-[(1E)-1-(4-Methylphenyl)-3-(pyrrolidin-1-yl)prop-1-en-1-yl]pyridin-2-yl}acrylic acid; MFCD00869830; Acrivastin; Duact; (2E)-3-{6-[(1E)-1-(4-methylphenyl)-3-(pyrrolidin-1-yl)prop-1-en-1-yl]pyridin-2-yl}prop-2-enoic acid |
| Molecular Formula | C22H24N2O2 |
| Molecular Weight | 348.44 |
| Purity | ≥98 (HPLC) |
| Density | 1.2±0.1 g/cm3 |
| Boiling Point | 555.1±50.0 °C at 760 mmHg |
| Melting Point | 55.5-59.5 °C(lit.) |
| Appearance | powder |
| Storage Condition | 2-8°C |
| Application | Acrivastine (BW825C) is a short-acting histamine 1 receptor antagonist used to treat allergic rhinitis. |
| PubChem ID | 329825170 |
| MDL Number | MFCD00869830 |
| SMILES | Cc1ccc(cc1)\C(=C/CN2CCCC2)c3cccc(\C=C\C(O)=O)n3 |
| InChI | 1S/C22H24N2O2/c1-17-7-9-18(10-8-17)20(13-16-24-14-2-3-15-24)21-6-4-5-19(23-21)11-12-22(25)26/h4-13H,2-3,14-16H2,1H3,(H,25,26)/b12-11+,20-13+ |
| InChI Key | PWACSDKDOHSSQD-IUTFFREVSA-N |
| NACRES Code | NA.77 |
| UNSPSC | 12352200 |
| MSDS | msds/9056_1_87848_99_5.pdf |
| Bioactivity | Acrivastine (BW825C) is a short acting histamine 1 receptor antagonist for the treatment of allergic rhinitis. Related Catalog Signaling Pathways >> GPCR/G Protein >> Histamine Receptor Signaling Pathways >> Immunology/Inflammation >> Histamine Receptor Research Areas >> Inflammation/Immunology In Vivo Acrivastine (usually 8mg three times daily) is an effective and well tolerated antihistamine in the treatment of chronic urticaria and allergic rhinitis. Acrivastine is more effective than placebo and similar in efficacy to clemastine or terfenadine in the treatment of seasonal allergic rhinitis. In the treatment of dermatoses in which histamine has a pathogenetic role, the efficacy of acrivastine is superior to that of placebo and similar to that of usual dosages of clemastine, hydroxyzine, chlorpheniramine, cyproheptadine or terfenadine. Acrivastine causes less drowsiness than clemastine, the incidence of adverse effects being indistinguishable from that with placebo or terfenadine[1]. Both 4 mg and 8 mg acrivastine alleviate the symptoms of seasonal allergic rhinitis with significant improvements in the symptom scores for sneezing, running nose and the calculated overall score. In addition, 8 mg acrivastine reduces the symptom scores for watery eyes and itchy throat. Acrivastine is both well tolerated and effective in the treatment of seasonal allergic rhinitis[2]. References [1]. Brogden RN, et al. Acrivastine. A review of its pharmacological properties and therapeutic efficacy in allergic rhinitis, urticaria and related disorders. Drugs. 1991 Jun;41(6):927-40. [2]. Gibbs TG, et al. Acrivastine in two doses compared with placebo in a multicentre, parallel group study for the treatment of seasonal allergic rhinitis. Br J Clin Pract. 1989 Jan;43(1):11-4. Chemical & Physical Properties Density 1.2±0.1 g/cm3 Boiling Point 555.1±50.0 °C at 760 mmHg Melting Point 55.5-59.5 °C(lit.) Molecular Formula C22H24N2O2 Molecular Weight 348.438 Flash Point 289.5±30.1 °C Exact Mass 348.183777 PSA 53.43000 LogP 4.55 Vapour Pressure 0.0±1.6 mmHg at 25°C Index of Refraction 1.627 InChIKey PWACSDKDOHSSQD-IUTFFREVSA-N SMILES Cc1ccc(C(=CCN2CCCC2)c2cccc(C=CC(=O)O)n2)cc1 Storage condition 2-8°C |
| Use of | Properties Articles28 Name acrivastine Synonym More Synonyms Acrivastine Biological Activity Related Catalog Signaling Pathways >> GPCR/G Protein >> Histamine Receptor Signaling Pathways >> Immunology/Inflammation >> Histamine Receptor Research Areas >> Inflammation/Immunology References [1]. Brogden RN, et al. Acrivastine. A review of its pharmacological properties and therapeutic efficacy in allergic rhinitis, urticaria and related disorders. Drugs. 1991 Jun;41(6):927-40. [2]. Gibbs TG, et al. Acrivastine in two doses compared with placebo in a multicentre, parallel group study for the treatment of seasonal allergic rhinitis. Br J Clin Pract. 1989 Jan;43(1):11-4. Chemical & Physical Properties Molecular Formula C22H24N2O2 Exact Mass 348.183777 PSA 53.43000 Index of Refraction 1.627 InChIKey PWACSDKDOHSSQD-IUTFFREVSA-N |
| Transport Info | Product Name: Avastin |
| Related Products in Specialty Chemicals | ||
|---|---|---|
| Acoxatrine | 748-44-7 | 2A-9009051 |
| Acridine | 260-94-6 | 2A-9009052 |
| Acridineorange | 494-38-2 | 2A-9009053 |
| Acrinathrin | 101007-06-1 | 2A-9009054 |
| Ethacridine lactate monohydrate | 6402-23-9 | 2A-9009055 |
| Actarit | 18699-02-0 | 2A-9009057 |
| Adibendan | 100510-33-6 | 2A-9009062 |
| Adinazolam | 37115-32-5 | 2A-9009063 |
| Adipiodone | 606-17-7 | 2A-9009064 |
| Adrafinil | 63547-13-7 | 2A-9009065 |
| Browse all Specialty Chemicals products » | ||
Phone:
630-322-8886
630-322-8887
Email:
Office Locations:
Chicago, IL, USA
San Francisco, CA, USA
EN
SDS